abc27

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...
St. Louis American

2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)’s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

TF overexpression is associated with thrombosis, metastasis and poor prognosis in solid tumors, including cervical and pancreatic cancer. MRG004A is a novel anti-TF monoclonal antibody conjugated (ADC ...
Seeking Alpha

Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal

Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...
FiercePharma

Lonza Group AG : Lonza enters development and manufacturing agreement with Genmab A/S

Lonza enters development and manufacturing agreement with Genmab A/S for a novel antibody drug conjugate (ADC), HuMax-TF TM • This agreement secures a development and cGMP manufacturing plan for ...
Nasdaq

Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

- ICON-2 is pharmacologically more potent in vivo and in vitro, with better nonclinical tolerability, compared with a monomethyl auristatin E (MMAE) anti-TF antibody-drug conjugate (ADC) - - Data ...
GEN

Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate

CMO will produce fully human HuMax-TF antibody and also construct final ADC candidate. Lonza is to provide Genmab with development and cGMP manufacturing expertise for the latter’s preclinical-stage ...
MarketWatch

2024ASCO Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug ...